C6M
A fragment of type VIa1 collagen released by MMP-2. Special beaded filament collagen measuring interstitial ECM destruction. A neo-epitope fragment of type VI collagen generated by matrix metalloproteinase activity, enabling non-invasive assessment of interstitial extracellular matrix remodeling in fibrotic and oncological conditions conditions.
Key features and values
- Quantifies degradation fragments of type VI collagen produced by matrix metalloproteinase activity.
- Reflects interstitial extracellular matrix remodeling associated with fibrogenesis and tumor progression.
- Provides a non-invasive measure of tissue remodeling in various pathological conditions.
- Supports monitoring of disease progression and response to therapies targeting extracellular matrix remodeling.
- Applicable in research on diseases characterized by excessive extracellular matrix turnover, such as liver fibrosis and cancer.
- Facilitates evaluation of interventions aimed at modulating extracellular matrix degradation.
- Complements other biomarkers for a comprehensive assessment of tissue remodeling dynamics.
Description
The C6M biomarker assay measures specific neo-epitope fragments of type VI collagen generated through matrix metalloproteinase activity, serving as an indicator of interstitial extracellular matrix remodeling. This non-invasive assay provides insights into pathological tissue remodeling processes, particularly in conditions such as liver fibrosis and cancer. By quantifying collagen degradation products associated with matrix metalloproteinase activity, the C6M assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of tissue remodeling. It serves as a valuable tool in both clinical and research settings for assessing the dynamics of extracellular matrix turnover.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
